Zantac and its generic versions contain carcinogen NDMA
While they have not been recalled, “possible carcinogens” have been detected in the heartburn drug Zantac, and its generic forms. Nitrosodimethylamine (NDMA) is the carcinogen detected by the U.S. Food and Drug Administration and European drug regulators.
An independent company named Valisure tested the drugs, and turned their findings over to the FDA. The FDA found that Zantac did in fact contain NDMA, but the FDA reported lower levels than those found by Valisure. This latest carcinogen contamination news comes after what’s been a year of recalls by the FDA, EU, and various drug manufacturers. Since July of 2018, Valsartan, Losartan, and Irbesartan have all been recalled due to various carcinogen contaminations.
Although the FDA and Zantac aren’t recalling the drugs, Valisure is hoping they do, as they’ve submitted a “citizen petition” aimed at recalling Zantac and its generic forms. The FDA wants consumers to know that the presence of NDMA in these drugs isn’t something to panic over. The FDA however is clear in their belief that NDMA should not be present in these drugs, and they’re “going to make sure they get out.”
To read the full article over at USAToday.com, click here: https://bit.ly/2lUOA5u